MET
MOLECULAR TARGETMET proto-oncogene, receptor tyrosine kinase
MET (MET proto-oncogene, receptor tyrosine kinase) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MET
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Crizotinib | 3.93 | 50 |
| 2 | Afatinib | 1.61 | 4 |
| 3 | egcg | 1.39 | 3 |
| 4 | Axitinib | 1.39 | 3 |
| 5 | Sorafenib | 1.10 | 2 |
| 6 | Quercetin | 0.69 | 1 |
| 7 | Adenosine Triphosphate | 0.69 | 1 |
| 8 | sp600125 | 0.69 | 1 |
About MET as a Drug Target
MET (MET proto-oncogene, receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented MET interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MET inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.